Overexpression of  &lt;i&gt;VIRMA&lt;/i&gt; Confers Vulnerability to Breast Cancers via the m &lt;sup&gt;6&lt;/sup&gt;A-Dependent Regulation of Unfolded Protein Response

Lee, Quintin; Song, Renhua; Phan, Dang Anh Vu; Pinello, Natalia; Su, Anni; Tieng, Jessica; Halstead, James M.; Wong, Alex C. H.; Geldermalsen, Michelle van; Lee, Bob S-L; Rong, Bowen; Cook, Kristina M.; Larance, Mark; Liu, Renjing; Lan, Fei; Wong, Justin Jong-Leong; Tiffen, Jessamy

doi:10.2139/ssrn.4179766

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…43 In SKBR3 cells, VIRMA upregulates m6A-modified lncRNA NEAT1, which accelerates BC cell proliferation. 73 In contrast, certain lncRNAs regulated by m6A…”

Section: Regulation Of Lncrnas By M6amentioning

confidence: 99%

“…LINC00667 functions as a sponge for miR‐556‐5p and positively regulates KIAA1429, resulting in a regenerative feedback loop of KIAA1429/m6A/LINC00667/miR‐556‐5p that promotes BC progression 43 . In SKBR3 cells, VIRMA upregulates m6A‐modified lncRNA NEAT1, which accelerates BC cell proliferation 73 . In contrast, certain lncRNAs regulated by m6A “writers” inhibit the progression of BC.…”

Section: Regulation Of Ncrnas By M6a In Bcmentioning

confidence: 99%

See 1 more Smart Citation

Unraveling the cross‐talk between N6‐methyladenosine modification and non‐coding RNAs in breast cancer: Mechanisms and clinical implications

Liu,

Xie,

Sui

et al. 2024

Intl Journal of Cancer

View full text Add to dashboard Cite

In recent years, breast cancer (BC) has surpassed lung cancer as the most common malignant tumor worldwide and remains the leading cause of cancer death in women. The etiology of BC usually involves dysregulation of epigenetic mechanisms and aberrant expression of certain non‐coding RNAs (ncRNAs). N6‐methyladenosine (m6A), the most prevalent RNA modification in eukaryotes, widely exists in ncRNAs to affect its biosynthesis and function, and is an important regulator of tumor‐related signaling pathways. Interestingly, ncRNAs can also regulate or target m6A modification, playing a key role in cancer progression. However, the m6A‐ncRNAs regulatory network in BC has not been fully elucidated, especially the regulation of m6A modification by ncRNAs. Therefore, in this review, we comprehensively summarize the interaction mechanisms and biological significance of m6A modifications and ncRNAs in BC. Meanwhile, we also focused on the clinical application value of m6A modification in BC diagnosis and prognosis, intending to explore new biomarkers and potential therapeutic targets.

show abstract

“…43 In SKBR3 cells, VIRMA upregulates m6A-modified lncRNA NEAT1, which accelerates BC cell proliferation. 73 In contrast, certain lncRNAs regulated by m6A…”

Section: Regulation Of Lncrnas By M6amentioning

confidence: 99%

Section: Regulation Of Ncrnas By M6a In Bcmentioning

confidence: 99%

Unraveling the cross‐talk between N6‐methyladenosine modification and non‐coding RNAs in breast cancer: Mechanisms and clinical implications

Liu,

Xie,

Sui

et al. 2024

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Moreover, ZC3H13 is responsible for m6A installation and plays critical roles in the proliferation of cancer cells [33]. VIRMA, also called KIAA1429, is important for specially depositing m6A methylation to 3′UTR region of mRNA [34,35].…”

Section: Enzymes and Proteins Involved In Modification By M6amentioning

confidence: 99%

Recent advances of m6A methylation in skeletal system disease

Liang,

Yi,

Liu

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Skeletal system disease (SSD) is defined as a class of chronic disorders of skeletal system with poor prognosis and causes heavy economic burden. m6A, methylation at the N6 position of adenosine in RNA, is a reversible and dynamic modification in posttranscriptional mRNA. Evidences suggest that m6A modifications play a crucial role in regulating biological processes of all kinds of diseases, such as malignancy. Recently studies have revealed that as the most abundant epigentic modification, m6A is involved in the progression of SSD. However, the function of m6A modification in SSD is not fully illustrated. Therefore, make clear the relationship between m6A modification and SSD pathogenesis might provide novel sights for prevention and targeted treatment of SSD. This article will summarize the recent advances of m6A regulation in the biological processes of SSD, including osteoporosis, osteosarcoma, rheumatoid arthritis and osteoarthritis, and discuss the potential clinical value, research challenge and future prospect of m6A modification in SSD.

show abstract

Overexpression of <i>VIRMA</i> Confers Vulnerability to Breast Cancers via the m <sup>6</sup>A-Dependent Regulation of Unfolded Protein Response

Cited by 2 publications

References 0 publications

Unraveling the cross‐talk between N6‐methyladenosine modification and non‐coding RNAs in breast cancer: Mechanisms and clinical implications

Unraveling the cross‐talk between N6‐methyladenosine modification and non‐coding RNAs in breast cancer: Mechanisms and clinical implications

Recent advances of m6A methylation in skeletal system disease

Contact Info

Product

Resources

About